Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,030.00

by · The Cerbat Gem

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price raised by Guggenheim from $1,000.00 to $1,030.00 in a research note issued to investors on Monday,Benzinga reports. Guggenheim currently has a buy rating on the biopharmaceutical company’s stock.

REGN has been the topic of several other research reports. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Sanford C. Bernstein dropped their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Citigroup downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $900.00 to $700.00 in a research note on Monday, May 18th. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Finally, Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $797.75.

Check Out Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $768.58 on Monday. The business has a 50-day moving average of $650.88 and a two-hundred day moving average of $711.54. The firm has a market capitalization of $81.25 billion, a PE ratio of 19.00, a P/E/G ratio of 1.34 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the company posted $12.81 EPS. The company’s revenue was up 16.7% compared to the same quarter last year. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 43.11 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Insider Activity

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Insigneo Advisory Services LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares in the last quarter. Guardian Wealth Advisors LLC NC raised its stake in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 14 shares during the period. Arjuna Capital boosted its holdings in Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 14 shares in the last quarter. TD Private Client Wealth LLC boosted its holdings in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 15 shares in the last quarter. Finally, MCF Advisors LLC grew its stake in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 15 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

  • Positive Sentiment: Analysts and quantitative models point to improving earnings-estimate revisions, suggesting potential near-term upside for REGN. Regeneron is also being highlighted as a relatively attractive value stock within the biomedical and genetics sector. Surging Earnings Estimates Signal Upside for Regeneron Stock
  • Positive Sentiment: Guggenheim raised its price target for Regeneron to $1,030, a notably bullish view that reflects confidence in the company’s earnings power and long-term pipeline. Citigroup also adjusted its target to $740. Guggenheim Increases Regeneron Price Target
  • Neutral Sentiment: Articles comparing REGN with Incyte (INCY) frame the decision as a value-investing choice rather than announcing a new company-specific development. Regeneron’s valuation remains supported by strong profitability and its previously reported quarterly earnings and revenue beat. REGN or INCY: Which Is the Better Value Stock Right Now?
  • Negative Sentiment: Multiple law firms announced or promoted a securities class action alleging that Regeneron and certain executives misled investors about the prospects and protocol of the Phase 3 Fianlimab-Libtayo melanoma trial. The trial’s failure reportedly contributed to a sharp prior selloff and an approximately $11 billion market-capitalization loss. Investors in the August 1, 2025–May 15, 2026 class period face a September 14, 2026 lead-plaintiff deadline. These announcements largely repeat the same allegations, but they reinforce litigation and reputational overhang. Regeneron Clinical Trials Lead to Securities Fraud Class Action

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Recommended Stories